Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001193125-26-110693
Filing Date
2026-03-17
Accepted
2026-03-17 16:03:20
Documents
77
Period of Report
2025-12-31

Document Format Files

Seq Description Document Type Size
1 10-K antx-20251231.htm   iXBRL 10-K 2789917
2 EX-4.3 antx-ex4_3.htm EX-4.3 41478
3 EX-10.11 antx-ex10_11.htm EX-10.11 50691
4 EX-23.1 antx-ex23_1.htm EX-23.1 4115
5 EX-31.1 antx-ex31_1.htm EX-31.1 17370
6 EX-31.2 antx-ex31_2.htm EX-31.2 17141
7 EX-32.1 antx-ex32_1.htm EX-32.1 9768
8 EX-32.2 antx-ex32_2.htm EX-32.2 9773
9 GRAPHIC img107836303_0.jpg GRAPHIC 157700
10 GRAPHIC img142662276_0.jpg GRAPHIC 25383
  Complete submission text file 0001193125-26-110693.txt   10409377

Data Files

Seq Description Document Type Size
11 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT antx-20251231.xsd EX-101.SCH 1236929
81 EXTRACTED XBRL INSTANCE DOCUMENT antx-20251231_htm.xml XML 1662121
Mailing Address 1300 EL CAMINO REAL, SUITE 100 MENLO PARK CA 94025
Business Address 1300 EL CAMINO REAL, SUITE 100 MENLO PARK CA 94025 (650) 331-9090
AN2 Therapeutics, Inc. (Filer) CIK: 0001880438 (see all company filings)

EIN.: 820606654 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-41331 | Film No.: 26761684
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)